Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants: Identification of two antigenic epitopes involved in phospholipid binding

Thrombosis and Haemostasis

Volumn 85, Issue 6, 2001, Pages 1048-1054

  Izumi, T ^a   Kim, S W ^a   Greist, A ^a   Macedo Ribeiro, S ^a   Fuentes Prior, P ^a   Bode, W ^a   Kane, W H ^a   Ortel, T L ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C2 domain; Epitope mapping; Factor V; Hemorrhagic inhibitor; Phospholipid binding

Indexed keywords

ALANINE; AMINO ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 ANTIBODY; GLUTAMINE; IMMUNOGLOBULIN G; LYSINE; PHOSPHOLIPID; PROTEIN ANTIBODY; THROMBIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; ASSAY; BINDING KINETICS; BLEEDING; CARBOXY TERMINAL SEQUENCE; CASE REPORT; ENZYME ASSAY; EPITOPE MAPPING; HUMAN; IMMUNOGENETICS; INHIBITION KINETICS; MALE; MUTANT; PHOSPHOLIPID MEMBRANE; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; STRUCTURE ANALYSIS;

EID: 0034970408     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615962     Document Type: Article

References (31)

1. Factor V
2. Blood coagulation factors V and VIII: Structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders
3. Clinical and laboratory manifestations of anti-factor V antibodies
4. Isolation and study of an acquired inhibitor of human coagulation factor V
5. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations
6. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin
7. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin
8. Redo cardiac surgery: Late bleeding complications from topical thrombin-induced factor V deficiency
9. Topical thrombin and acquired coagulation factor inhibitors: Clinical spectrum and laboratory diagnosis
10. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin
11. Hemorrhagic death associated with a high titer factor V inhibitor
12. Severe bleeding caused by an inhibitor to coagulation factor V: A case report
13. Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto's disease and bullous pemphigoid
14. Crystal structures of the membrane-binding C2 domain of human coagulation factor V
15. Identification of functionally important amino acid residues within C2 domain of human factor V using alanine scanning mutagenesis
16. Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region
17. Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras
18. Characterization of an acquired inhibitor to coagulation factor V. Antibody binding to the second C-type domain of factor V inhibits the binding of factor V to phosphatidylserine and neutralizes procoagulant activity
19. Characterization of the phospholipid binding site in the second C-type domain of factor VIII
20. Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain
21. Mutations in a potential phospholipid binding loop in the C2 domain of factor V affecting the assembly of the prothrombinase complex
22. The complete cDNA sequence of bovine coagulation factor V
23. Electrostatic and hydrophobic interactions are involved in factor Va binding to membranes containing acidic phospholipids
24. Membrane binding kinetics of factor VIII indicate a complex binding process
25. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins
26. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid
27. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine
28. Structure of the C2 domain of human factor VIII at 1.5 Å resolution
29. Factor VIII inhibitors that bind to the N-terminal region of the C2 domain neutralize procoagulant activity and block binding to phosphatidylserine
30. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation